Form 4 for ALZN Alzamend Neuro, Inc.
Accepted 2022-02-01 00:00:00 ET · period of report 2022-02-01 · accession 0001214659-22-001599 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-01 | 2022-02-01 | ALZN | AULT MILTON C III | 10% | M - OptEx | $0.00 | +2.25M | 2.50M | +900% | $0 |
| D | 2022-02-01 | 2022-02-01 | ALZN | AULT MILTON C III | 10% | M - OptEx | $0.00 | -2.25M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-01 | M | A | 2,250,000 | $0.00 | 2,500,000 | D | — | — | |
| 2 | Derivative | Stock Options (Right to Buy) | 2022-02-01 | M | D | 2,250,000 | $0.00 | 0 | D | $0.00 · — to 2026-04-29 | 2,250,000 Common Stock | (F5) The stock options exercised in this transaction were fully vested and exercisable as of the transaction date. |